IntroductionMental illness has a chronic course of illness with a number of clinical manifestations. Affected individuals experience significant functional, emotional, cognitive, and/or behavioral impairments. The growing prevalence of mental illness has been associated with significant social and economic costs. Indeed, the economic burden of mental illness...
The Yale Manual for Psilocybin-Assisted Therapy of Depression provides researchers and therapists with methods, structure, and areas to consider regarding the use of psychedelic- assisted therapy in the treatment of Major Depressive Disorder (MDD). In particular, this manual illustrates a mode of utilizing Acceptance and Commitment Therapy (ACT) as a therape...
## Aim Investigate accounts from breath-holding freedivers about high efficiency in coping with adversity and pain, immediately quitting addictions, attaining harmonious meaningful life, becoming perspicacious and compassionate, getting spontaneous religious experience. ## Findings Full Mystical Experience is confirmed to happen in freediving, i.e. it is the...
ObjectiveResearch into psychedelic therapy models has shown promise for the treatment of specific psychiatric conditions. Mystical-type experiences occasioned by psilocybin have been correlated with therapeutic benefits and long-term improvements in positive mental outlook and attitudes. This article aims to provide an overview of the topic, highlight streng...
Combinations of psychotherapy with antidepressants are gold-standard psychiatric treatments. They operate through complex and interactional mechanisms, not unlike the reemergent paradigm of psychedelic-assisted psychotherapy, which promising research suggests may also be highly effective in even challenging populations. We review the therapeutic mechanisms b...
Objectives: To investigate the safety of psychedelics for humans, to identify the limitations of the current evidence and to indicate how gaps and limitations may be addressed in future clinical trial design. Methodology: I completed a narrative review of the literature to investigate the safety profile and known adverse effects of psychedelics, with a speci...
Background: Microdosing psychedelics - the practice of taking small, sub-hallucinogenic doses of substances like LSD or psilocybin-containing mushrooms - is becoming increasingly popular. Despite its surging popularity, little is known about the effects of this practice. Aims: This research had three main aims. First, we attempted to replicate previous findi...
Objective: The objective of this selective EBM review is to determine whether or not psilocybin is an effective treatment to reduce depression and anxiety in cancer patients with a diagnosis of an anxiety disorder, mood disorder, and/or stress disorder. Study design: Systematic review of three cross-over randomized placebo-controlled trials published in peer...
Microdosing psychedelics - the regular consumption of small amounts of psychedelic substances such as LSD or psilocybin - is a growing trend in popular culture. Recent studies on full-dose psychedelic psychotherapy reveal promising benefits for mental well-being, especially for depression and end-of-life anxiety. While full-dose therapies include perception-...
Serotonin (5-hydroxytryptamine, 5-HT)2A receptor agonists have recently emerged as promising new treatment options for a variety of disorders. The recent success of these agonists, also known as psychedelics, like psilocybin for the treatment of anxiety, depression, obsessive-compulsive disorder (OCD), and addiction, has ushered in a renaissance in the way t...
OBJECTIVE: The objective of this selective Evidence Based Medicine (EBM) review is to determine whether or not “Are psychedelics effective in treating anxiety associated with a lifethreatening disease?” STUDY DESIGN: Review of two double-blind, randomized, placebo-controlled pilot studies and one randomized controlled trial (RCT). DATA SOURCES: All studies w...
IntroductionEvidence based treatment for Substance use disorders (SUD) includes psychotherapy and pharmacotherapy. However, these are only partially effective. Hallucinogens, such as psilocybin, may represent potential new treatment options for SUD. This review provides a summary of (human) studies on the putative therapeutic effects of psilocybin, and discu...
Psilocybin-occasioned mystical experiences have been linked to persisting effects in healthy volunteers including positive changes in behavior, attitudes, and values, and increases in the personality domain of openness. In an open-label pilot-study of psilocybin-facilitated smoking addiction treatment, 15 smokers received 2 or 3 doses of psilocybin in the co...
BackgroundThis report documents the phenomenology of the subjective experiences of 15 healthy psychedelic experienced volunteers who were involved in a functional magnetic resonance imaging (fMRI) study that was designed to image the brain effects of intravenous psilocybin.MethodsThe participants underwent a semi-structured interview exploring the effects of...
Acknowledgments Introduction: Neuropsychopharmacology as Spiritual Technology 1. Psychedelic Revival 2. Swiss Psilocybin and US Dollars 3. The Varieties of Psychedelic Lab Experience 4. Enacting Experimental Psychoses 5. Between Animality and Divinity 6. Mystic Materialism Conclusion: Fieldwork in Perennial Philosophy Notes Bibliography Index
Introduction and aimsSimultaneous polysubstance use (SPU) is a common phenomenon, yet little is known about its role in substance use initiation.Design and methodsIn the present study, 226 cannabis users completed structured interviews about their substance use history. For each substance ever used, participants provided details of their age of first use, th...
Hallucinogens. Nichols DE. Pharmacol Ther. 2004;101:131-181National Institute on Drug Abuse Web Site. Available at http://www.drugabuse.govThe Psychopharmacology of Hallucinogens. Abraham HD, Aldridge AM, Gogia P. Neuropsychopharmacol. 1996;14:285-298Toxic Psychoses as Pharmacological Models of Schizophrenia. Potvin S, Stip E, Roy J. Curr Psychiatr Rev. 2005...
